Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)

NCT02741557 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus
HIV Infections

Interventions

DRUG: DTG
DRUG: RPV
DRUG: DTG/RPV FDC

Sponsor

ViiV Healthcare

Collaborators

[object Object]